Chemical formula: C₁₃H₁₈N₄O₃ Molecular mass: 278.307 g/mol PubChem compound: 4740
Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C04AD03 | Pentoxifylline | C Cardiovascular system → C04 Peripheral vasodilators → C04A Peripheral vasodilators → C04AD Purine derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TRENTAL 400 Modified release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Pentoxifylline is an active ingredient of these brands:
Austria (AT)Brazil (BR)Ecuador (EC)Finland (FI)Germany (DE)Israel (IL)Malta (MT)Mexico (MX)Netherlands (NL)New Zealand (NZ)Poland (PL)Tunisia (TN)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
